Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Article

June 1, 2001

5-FU cream formulation displays unique profile

Washington - The new 5-fluorouracil (5-FU) 0.5 percent topical cream (Carac) indicated for the treatment of actinic keratoses offers more targeted drug delivery along with the potential for a more favorable safety profile than a previously available formulation containing a 10-fold higher concentration of active ingredient, according to results from comparative studies presented at the annual meeting of the American Academy of Dermatology.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!